Business Insights | Mitigating the Hidden Real Estate Costs in Life Sciences M&A

Life sciences companies are operating in an era of sustained, high-value M&A. Each year, large pharmaceutical organizations acquire multiple sponsor‑built biotech companies with small real estate footprints, lean headcounts and significant enterprise value. Individually, these acquisitions appear operationally modest. Collectively, they introduce material operating and value‑protection risk if they are not deliberately integrated into the enterprise.

For heads of corporate real estate (CRE), the challenges multiply. Acquired biotechs are frequently tucked in when an acquisition closes to preserve scientific momentum and avoid disruption. Over time, this approach produces an expanding portfolio of unintegrated entities with different systems and processes. Financial reporting remains intact, but the operating model doesn't fully absorb the acquired biotech.

This condition, referred to as stranding, is structural rather than accidental. It emerges from the combination of small footprints, high deal cadence and a lack of standard CRE processes for serial acquisitions.

This article introduces a practical CRE playbook for serial life sciences acquirers, providing CRE leaders with a defensible, low‑disruption operating model. When applied consistently, the playbook protects value, reduces preventable post‑close exposure and builds institutional capability that compounds across acquisitions.

The Operating Reality of Sponsor-Built Biotech Acquisitions

Recent life sciences M&A activity demonstrates a pattern. Large pharmaceutical organizations complete multiple, high‑value acquisitions of single therapeutic assets or platforms developed by sponsor-backed biotech companies.

These transactions share characteristics that shape real estate and workplace decisions, such as:

• Limited physical footprints of one to four facilities
• Lean headcount typically below 600 employees
• High deal values ranging from $1 billion to $15 billion
• Frequent cadence of transactions each year

Individually, these characteristics argue against heavy integration upon closing. Instead, the acquired companies are frequently tucked in to preserve scientific momentum and avoid disruption.

However, this approach produces an expanding portfolio of unintegrated entities with different systems, service standards, environmental health and safety (EHS) protocols and sustainability reporting frameworks. The entities continue to operate as they did before—renewing leases, refreshing laboratories, rolling over service contracts and continuing local practices—outside the visibility or governance of the parent organization.

For CRE leaders, the real estate portfolios they inherit are difficult to view, govern and optimize, and the challenges grow more severe over time.

Identifying Stranding in the Portfolio

Serial life sciences acquirers develop portfolios of businesses that are financially integrated but only partially absorbed from an operational standpoint. While these entities continue to create value, they do not fully operate as part of the enterprise—a practical signature of stranding.

Stranded portfolios exhibit a consistent set of signals, including:

• Fragmented systems. The portfolio relies on multiple integrated workplace management systems, computer-aided facility management software or lease administration platforms without a unified portfolio view.
• Passive lease outcomes. Leases renew on legacy terms without portfolio‑level analysis or decision making.
• Inconsistent EHS and sustainability reporting. Enterprise reporting requires manual consolidation across acquired properties.

When two or more of these conditions are present, the portfolio is not operating as an integrated whole. Allowing these entities to remain only partially integrated can significantly erode enterprise value over time.

Estimating the Cost of Inaction

CRE integration decisions influence a measurable share of outcomes following an acquisition, though there is no published M&A research on value erosion by company function.

A conservative baseline for CRE‑attributable risk holds preventable exposure at 1% of deal value. For large organizations, this exposure compounds across acquisitions and can exceed $100 million over multiple years.

This estimate is meant to indicate relative scale, not a precise measurement. Modest and repeatable CRE investments can protect enterprise value.

Integration, Not Consolidation

In the world of life sciences M&A, integration is often equated with consolidation—a process that includes disruptive measures such as closing sites, relocating teams or imposing uniform standards. For sponsor‑built biotechs, this approach can destroy value rather than protect it.

Effective integration does just the opposite. It preserves the scientific momentum, team cohesion and operating distinctiveness of the acquired biotech, while making it operable within the enterprise. Because real estate, workplace services, systems and compliance converge at the physical site, CRE teams are best positioned to address the six dimensions of integration decisions:

• Culture
• Service level
• Real estate systems
• Data governance
• Environmental, health and safety
• Sustainability

Addressing these dimensions deliberately protects the value of each transaction and the enterprise. The objective isn't to make every acquired biotech look the same, but to make them governable.

A CRE Playbook for Serial Acquisition Integration

Serial acquirers should rely on an operating model designed for repetition. The recommended CRE playbook has two components: capturing an operating baseline for every acquired company within three months and conducting periodic reviews that align accumulated acquisitions with enterprise standards.

Component 1: The Day‑90 Picture

The enterprise CRE team captures a baseline of the acquired company's real estate operations within the first 90 days of an acquisition by documenting the following:

• Facilities and leases
• Key lease dates and capital expenditure milestones
• Laboratory and infrastructure conditions
• Systems in use
• Decision makers and stakeholders
• Variance from enterprise standards

This baseline is a minimum viable record captured while the information is accurate and accessible.

Component 2: The Threading Review

Every 18 to 24 months, the CRE team conducts a portfolio‑level review that reconciles the acquisitions against enterprise standards. The review produces the following outputs:

• A portfolio heat map across integration dimensions
• A prioritized remediation plan
• A forward-looking operating model for future acquisitions

Together, these components establish a managed operating cycle, minimizing accumulation risk following a period of heightened acquisition activity.

Model Ownership, Governance and Cost

CRE leaders own this operating model end to end and work with corporate development, human resources, EHS and integration teams to implement it. The model is designed to run alongside the deal and integration processes without extending timelines.

Compared with the value at risk, the costs of implementing this model are relatively modest and predictable. More importantly, with this model in place, each acquisition strengthens the enterprise rather than adding unmanaged complexity.

Looking Ahead

Stranding is a consequence of how large enterprises choose to integrate acquired biotechs. As life sciences M&A continues, CRE leaders have a limited window to institutionalize practices that protect value without disrupting the scientific engine that acquisitions are meant to preserve. For serial life sciences acquirers, the issue isn't whether another acquisition is coming, but whether the enterprise is prepared to absorb it strategically.